Photoreceptor-directed light therapy in Parkinson’s disease

Not Applicable

Completed

• Conditions: Parkinson's disease; Circadian disruption; Sleep disruption; Neurological - Parkinson's disease

• Registration Number: ACTRN12621000077864
• Lead Sponsor: Queensland University of Technology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-01-29
• Study Completion: 2022-12-06
• Last Update Posted: 27 February 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• People with PD based on the unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Hoehn & Yahr staging (I-IV).
• Healthy eyes with no anterior eye disease (i.e. lens opacities < grade 2 based on LOCS III) and no signs of retinal or optic nerve disease (diabetic retinopathy, glaucoma or age-related macular degeneration) based on ophthalmic examination (determined by an ophthalmologist, PI Feigl)
•Living independently in the community and able to walk unaided

Exclusion Criteria

•Inability to comply with study follow up
•Participants having travelled across 2 or more time zones within 90 days before start of the study
•Dementia based on MMSE (<24) and ACE (<82) assessments
•Deep brain stimulation, other device assisted therapies (i.e. red light therapy) or CNS surgery
•Any type of systemic disease or any medical condition (controlled or uncontrolled) other than PD that could be expected to significantly affect the health of a participant
•A periodic limb movement disorder index (PLMI) > 15/hour in PSG
•Significant sleep apnea (AHI apnoea-hypnoea index > 15 events/hour) and loss of REM atonia in PSG
•Recent or recurrent history of musculoskeletal injury or surgery

Study & Design

• Study Type: Interventional
• Study Design: Not specified